California Doc Banned from Prescribing Pills: License Lapse Bites Hard
Published Date: 5/22/2025
Notice
Summary
Dr. Khursheed Haider from California lost his DEA registration because his medical license expired and he can no longer legally handle controlled substances. He didn’t ask for a hearing, so the DEA officially revoked his registration starting May 22, 2025. This means Dr. Haider can’t prescribe or manage controlled drugs anymore, affecting his medical practice and patients.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
Pending Renewals and New Registrations Denied
The DEA denied any pending applications by Dr. Khursheed Haider to renew or modify his DEA registration and denied any other pending application for additional registration in California. That denial is effective June 23, 2025, preventing him from regaining DEA registration through those pending applications.
DEA Registration Revoked; No Controlled Drugs
Dr. Khursheed Haider’s DEA registration was revoked and the Order is effective June 23, 2025. He can no longer legally prescribe, administer, dispense, or otherwise handle controlled substances in California. This affects his medical practice and patients who receive controlled-drug prescriptions from him.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-12144 — Importer of Controlled Substances Application: Wedgewood Pharmacy LLC
Wedgewood Pharmacy LLC wants to become an official importer of certain strong controlled substances, like Etorphine HCL and Thiafentanil. This affects drug manufacturers and others in the supply chain who can comment or request a hearing by July 17, 2026. No direct costs are mentioned, but the decision could impact how these drugs enter the U.S. market.
2026-12143 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
2026-12140 — Importer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to become an official importer of some controlled substances like ibogaine and marijuana. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how these substances are brought into the U.S., but no costs or fees are mentioned yet.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
Previous / Next Documents
Previous: 2025-09220 — New Postal Products
The Postal Service just filed a new deal for special mail services, and the Commission is checking it out. This affects businesses and customers who use these special mail options, with possible changes in prices or services soon. The public can share their thoughts before any decisions are made, so keep an eye out!
Next: 2025-09226 — Agency Information Collection Activities: Comment Request
The Consumer Financial Protection Bureau (CFPB) wants to keep using a form that helps companies join their complaint system. This affects businesses that handle consumer complaints and keeps things running smoothly without extra costs. They’re asking for approval to continue collecting this info, so no big changes or new fees are coming.